These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1251394)

  • 1. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R
    Tidsskr Nor Laegeforen; 1976 Feb; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K; Ho YM
    Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Metoclopramide in parkinsonism.
    Tarsy D; Parkes JD; Marsden CD
    Lancet; 1975 May; 1(7918):1244-5. PubMed ID: 48872
    [No Abstract]   [Full Text] [Related]  

  • 4. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 5. [L-dopa therapy for Parkinsonism and its relationship to surgical methods of treatments].
    Vasin NIa; Il'inskiĭ IA; Safronov VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(5):701-6. PubMed ID: 4454895
    [No Abstract]   [Full Text] [Related]  

  • 6. Sinemet and the treatment of Parkinsonism.
    Boshes B
    Ann Intern Med; 1981 Mar; 94(3):364-70. PubMed ID: 7013595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 9. [Acute psychotic status after sudden interruption of treatment of Parkinsonism with levodopa].
    Ledić P; Sepcić J; Antoncić N
    Neurologija; 1977; 25(1-2):95-7. PubMed ID: 616879
    [No Abstract]   [Full Text] [Related]  

  • 10. [Side-effects of L-dopa therapy].
    Girke W; Xenakis Ch
    Dtsch Med Wochenschr; 1975 Oct; 100(42):2165-9. PubMed ID: 1100342
    [No Abstract]   [Full Text] [Related]  

  • 11. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J
    Med Welt; 1979 Nov; 30(46):1740-2. PubMed ID: 537499
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of dihydroergotamine in the prevention and treatment of orthostatic hypotension syndromes in patients with parkinsonism treated with L-dopa].
    Jubert Gruart J; Balcells Riba M
    Arch Neurobiol (Madr); 1974; 37(4):401-12. PubMed ID: 4433212
    [No Abstract]   [Full Text] [Related]  

  • 16. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of the preparation L-dopa in parkinsonism].
    Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI
    Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837
    [No Abstract]   [Full Text] [Related]  

  • 18. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
    Steiger MJ; Quinn NP; Marsden CD
    Mov Disord; 1991; 6(1):91-2. PubMed ID: 2005934
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 20. [L-dopa-induced psychoses and their treatment with L-tryptophan].
    Demling J
    Fortschr Med; 1986 Apr; 104(17):360-2. PubMed ID: 3710403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.